Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ACLX 001

Next Previous
Drug Profile

ACLX 001

Alternative Names: ACLX-001; ARC-T/sparX-BCMA - Arcellx

Latest Information Update: 28 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arcellx
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Autoimmune disorders; Multiple myeloma

Most Recent Events

  • 28 Mar 2025 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (Parenteral)
  • 28 Jan 2025 No recent reports of development identified for phase-I development in Multiple-myeloma(Second-line therapy or greater) in USA (Parenteral)
  • 27 May 2024 Arcellx has patent pending for ddBC and SparX technology in the US, Europe, Australia, Eurasia, Israeli, Indonesia, India, Japan, Mexico, Singapore, South Africa, Hong Kong, Monaco, Philippines, New Zealand, South Korea

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top